ARTV (STOCKS)
Artiva Biotherapeutics, Inc. Common Stock
$9.670000
+1.130000 (+13.23%)
Prev close: $8.540000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Fred Aslan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $239.01M
- Employees
- 105
- P/E (TTM)
- -2.41
- P/B (TTM)
- 2.40
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.95 | $-0.89 | -0.0604 | -6.79% |
|
Dec 2025 (Q4)
|
$-0.85 | $-0.84 | -0.0071 | -0.84% |
|
Sep 2025 (Q3)
|
$-0.88 | $-0.89 | +0.0074 | +0.83% |
|
Jun 2025 (Q2)
|
$-0.87 | $-0.82 | -0.0472 | -5.74% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $5.00M |
| Operating Expenses | $92.07M |
| Research and Development | $71.80M |
| Other Operating Expenses | $20.27M |
| Operating Income/Loss | -$92.07M |
| Income/Loss From Continuing Operations After Tax | -$87.07M |
| Income/Loss From Continuing Operations Before Tax | -$87.07M |
| Net Income/Loss | -$87.07M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$87.07M |
| Net Income/Loss Available To Common Stockholders, Basic | -$87.07M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.54 |
| Diluted Earnings Per Share | -$3.54 |
| Basic Average Shares | 73,581,669 |
| Diluted Average Shares | 73,581,669 |
| Assets | $105.96M |
| Current Assets | $88.74M |
| Cash | $86.80M |
| Other Current Assets | $1.94M |
| Noncurrent Assets | $17.22M |
| Fixed Assets | $6.22M |
| Other Non-current Assets | $11.00M |
| Liabilities | $18.11M |
| Current Liabilities | $10.88M |
| Accounts Payable | $2.29M |
| Wages | $3.18M |
| Other Current Liabilities | $5.41M |
| Noncurrent Liabilities | $7.23M |
| Equity | $87.85M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $87.85M |
| Liabilities And Equity | $105.96M |
| Net Cash Flow From Operating Activities | -$77.86M |
| Net Cash Flow From Operating Activities, Continuing | -$77.86M |
| Net Cash Flow From Investing Activities | $68.76M |
| Net Cash Flow From Investing Activities, Continuing | $68.76M |
| Net Cash Flow From Financing Activities | -$342.00K |
| Net Cash Flow From Financing Activities, Continuing | -$342.00K |
| Net Cash Flow | -$9.45M |
| Net Cash Flow, Continuing | -$9.45M |
| Comprehensive Income/Loss | -$87.09M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$87.09M |
| Other Comprehensive Income/Loss | -$65.84M |